CL2016001368A1 - Inhibidores de cinasa serina/treonina - Google Patents

Inhibidores de cinasa serina/treonina

Info

Publication number
CL2016001368A1
CL2016001368A1 CL2016001368A CL2016001368A CL2016001368A1 CL 2016001368 A1 CL2016001368 A1 CL 2016001368A1 CL 2016001368 A CL2016001368 A CL 2016001368A CL 2016001368 A CL2016001368 A CL 2016001368A CL 2016001368 A1 CL2016001368 A1 CL 2016001368A1
Authority
CL
Chile
Prior art keywords
serine
kinase inhibitors
threonine kinase
cancer
mielogen
Prior art date
Application number
CL2016001368A
Other languages
English (en)
Inventor
Aleksandr Kolesnikov
Steven Do
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2016001368A1 publication Critical patent/CL2016001368A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

COMPUESTO DERIVADO DE [1,2,4]TRIAZOLO[3,4,5-DE]QUINAZOLIN-PIRIMIDIN-AMINA, INHIBIDORES DE SERINA/TREONINA QUINASA; COMPOSICION FARMACEUTICA; Y SU USO PARA EL TRATAMIENTO DE UN TRASTORNO PROLIFERATIVO, SELECCIONADO DE LEUCEMIA MIELOGENA AGUDA, CANCER PANCREATICO, CANCER DE LA TIROIDES, CANCER DE OVARIOS, MELANOMA, ENTRE OTROS.
CL2016001368A 2013-12-06 2016-06-03 Inhibidores de cinasa serina/treonina CL2016001368A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361912905P 2013-12-06 2013-12-06

Publications (1)

Publication Number Publication Date
CL2016001368A1 true CL2016001368A1 (es) 2016-12-09

Family

ID=52350292

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001368A CL2016001368A1 (es) 2013-12-06 2016-06-03 Inhibidores de cinasa serina/treonina

Country Status (23)

Country Link
US (5) US9867833B2 (es)
EP (1) EP3077401B1 (es)
JP (2) JP6449293B2 (es)
KR (1) KR102359759B1 (es)
CN (1) CN106029672B (es)
AR (1) AR098647A1 (es)
AU (1) AU2014360455B2 (es)
BR (1) BR112016012844B1 (es)
CA (1) CA2932729C (es)
CL (1) CL2016001368A1 (es)
CR (1) CR20160309A (es)
EA (1) EA031243B1 (es)
IL (1) IL246017B (es)
MA (1) MA39170B1 (es)
MX (1) MX368443B (es)
MY (1) MY176049A (es)
PE (1) PE20160886A1 (es)
PH (1) PH12016501071A1 (es)
SG (1) SG11201604573WA (es)
TW (1) TWI557126B (es)
UA (1) UA120506C2 (es)
WO (1) WO2015085007A1 (es)
ZA (1) ZA201604461B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104755478B (zh) 2012-10-16 2017-10-10 霍夫曼-拉罗奇有限公司 丝氨酸/苏氨酸激酶抑制剂
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
UA120506C2 (uk) 2013-12-06 2019-12-26 Дженентек, Інк. Інгібітори серин/треонінкіназ
EP3089788B1 (en) 2013-12-30 2018-10-24 Genentech, Inc. Serine/threonine kinase inhibitors
WO2015103137A1 (en) 2013-12-30 2015-07-09 Array Biopharma Inc. Serine/threonine kinase inhibitors
JP6877423B2 (ja) 2015-11-09 2021-05-26 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ がんの処置において有用なジヒドロイミダゾピラジノン誘導体
WO2017180581A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Diagnostic and therapeutic methods for cancer
JP2020532982A (ja) 2017-09-08 2020-11-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの診断及び治療方法
WO2019158579A1 (en) 2018-02-13 2019-08-22 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
JP7433898B2 (ja) 2019-12-26 2024-02-20 キヤノン株式会社 光電変換素子、光電変換システム

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508358A (ja) * 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
BRPI0615940A2 (pt) * 2005-09-15 2016-08-23 Painceptor Pharma Corp métodos de modular a interação de uma neurotrofina e um receptor de neurotrofina, de tratar dor em um indivíduo, de tratar distúrbio inflamatório em um indivíduo, de tratar um distúrbio neurológico em um indivíduo e de tratar uma doença ou distúrbio associado aos sistemas geniturinário e/ou gastrointestinal de um indivíduo, e, composto
CA2672213C (en) * 2006-12-22 2016-02-16 Astex Therapeutics Limited Bicyclic amine derivatives as protein tyrosine kinase inhibitors
DE602008003055D1 (de) * 2007-05-31 2010-12-02 Nerviano Medical Sciences Srl Zyklokondensierte Azaindole, die als Kinase-Hemmer wirken
ES2644230T3 (es) 2010-11-23 2017-11-28 Abbvie Inc. Sales y formas cristalinas de un agente inductor de apoptosis
CN103635472B (zh) 2011-02-28 2018-01-12 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
WO2013020062A1 (en) 2011-08-04 2013-02-07 Array Biopharma Inc. Quinazoline compounds as serine/threonine kinase inhibitors
CN106349217B (zh) 2012-03-01 2020-08-28 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
EP2888247B1 (en) 2012-08-27 2020-03-25 Array Biopharma, Inc. Serine/threonine kinase inhibitors for the treatment of hyperproliferative diseases
CN104755478B (zh) 2012-10-16 2017-10-10 霍夫曼-拉罗奇有限公司 丝氨酸/苏氨酸激酶抑制剂
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
UA120506C2 (uk) 2013-12-06 2019-12-26 Дженентек, Інк. Інгібітори серин/треонінкіназ
EP3089788B1 (en) 2013-12-30 2018-10-24 Genentech, Inc. Serine/threonine kinase inhibitors
WO2015103137A1 (en) 2013-12-30 2015-07-09 Array Biopharma Inc. Serine/threonine kinase inhibitors
CA2945098C (en) 2014-04-09 2022-10-04 Genentech, Inc. Process for the manufacturing of medicaments

Also Published As

Publication number Publication date
EA031243B1 (ru) 2018-12-28
US20190192534A1 (en) 2019-06-27
PE20160886A1 (es) 2016-09-14
MY176049A (en) 2020-07-22
AU2014360455A1 (en) 2016-07-07
MA39170A1 (fr) 2018-04-30
KR102359759B1 (ko) 2022-02-09
TWI557126B (zh) 2016-11-11
US9867833B2 (en) 2018-01-16
NZ721361A (en) 2021-07-30
US20180000833A1 (en) 2018-01-04
JP2019034970A (ja) 2019-03-07
CR20160309A (es) 2016-08-25
US20210106593A1 (en) 2021-04-15
SG11201604573WA (en) 2016-07-28
WO2015085007A1 (en) 2015-06-11
MX2016007352A (es) 2016-09-08
EA201691177A1 (ru) 2016-10-31
IL246017B (en) 2019-10-31
CN106029672A (zh) 2016-10-12
BR112016012844B1 (pt) 2023-01-10
US11376260B2 (en) 2022-07-05
JP2016539153A (ja) 2016-12-15
JP6449293B2 (ja) 2019-01-09
CN106029672B (zh) 2019-03-29
MA39170B1 (fr) 2019-05-31
IL246017A0 (en) 2016-08-02
PH12016501071B1 (en) 2016-07-25
US20200078371A1 (en) 2020-03-12
CA2932729A1 (en) 2015-06-11
TW201522338A (zh) 2015-06-16
AR098647A1 (es) 2016-06-01
BR112016012844A2 (es) 2017-08-08
ZA201604461B (en) 2022-05-25
UA120506C2 (uk) 2019-12-26
PH12016501071A1 (en) 2016-07-25
AU2014360455B2 (en) 2018-05-10
US10278975B2 (en) 2019-05-07
EP3077401B1 (en) 2018-04-18
EP3077401A1 (en) 2016-10-12
CA2932729C (en) 2021-02-23
KR20160093703A (ko) 2016-08-08
US10842799B2 (en) 2020-11-24
US10517878B2 (en) 2019-12-31
MX368443B (es) 2019-10-02
US20150182537A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
CL2016001368A1 (es) Inhibidores de cinasa serina/treonina
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
CL2019000542A1 (es) Compuestos de tetraciclina y métodos de uso de los mismos.
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
CL2016000925A1 (es) Inhibidores de bromodominio
CL2015002932A1 (es) Inhibidores de proteína quinasa
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2015002194A1 (es) Inhbidores de erk y sus usos
CL2016001537A1 (es) Inhibidores de syk
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
UY35500A (es) Indazoles sustituidos con heteroarilo
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CL2015003735A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
CL2013002430A1 (es) Compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de proteina kinasa trk; composicion farmaceutica; compuesto intermediarios; utiles para el tratamiento de carcinoma pailar de tiroides, cancer de pancreas, cancer de colon y carcinoma de mama, entre otras.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2015015421A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
CR20150524A (es) Compuestos de heteroarilo y sus usos
JO3433B1 (ar) حلقة كاربوكسامايد ذات أربع أعضاء للاستخدام كمبيدات النيماتودا
MX2015015417A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
CL2015003147A1 (es) Compuestos de biheteroarilo y usos de los mismos
EA201591960A1 (ru) Ингибиторы акк и их применение